Media
Press releases
-
Oncopeptides strengthens its corporate communications function by appointing Rolf Gulliksen as Global Head of Corporate Communications
STOCKHOLM — April 2, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Rolf Gulliksen has been appointed global head of corporate com... -
Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study
STOCKHOLM — March 26, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today the final topline results from the pivotal phase 2 HORIZON study eva... -
The Lancet Haematology Publishes Results from Oncopeptides’ Multicenter, International Phase 1/2 Study (O-12-M1)
Stockholm — March 24, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the publication of results from its O-12-M1 study, melflufen plu... -
Oncopeptides provides update regarding COVID-19 impact on the melflufen clinical program
STOCKHOLM — March 20, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today measures the company is taking in response to the global spread of ...